For example, KRAS mutations were correlated with a poor clinical outcome in pancreatic [78] and lung cancer patients [79], TP53 mutation predicted poor survival in lung cancer patients [80], and STK11 mutations were negatively correlated with patients’ survival with NSCLC [81,82]. This evidence concerns the gene TP53 and lung cancer.